161 related articles for article (PubMed ID: 36240786)
1. Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer.
Chandekar KR; Singh H; Kumar R; Kumar S; Kakkar N; Mittal BR; Singh SK
Clin Nucl Med; 2023 Jan; 48(1):e1-e8. PubMed ID: 36240786
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
5. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
6.
De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
[TBL] [Abstract][Full Text] [Related]
7. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
8. Comparison of
Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
[TBL] [Abstract][Full Text] [Related]
9. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
10. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
11. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
12. A prospective head-to-head comparison of [
Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
[TBL] [Abstract][Full Text] [Related]
13. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
14. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study.
Wang G; Li L; Zang J; Hong H; Zhu L; Kung HF; Zhu Z
Clin Nucl Med; 2023 Apr; 48(4):289-295. PubMed ID: 36727866
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
17.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study.
Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG
J Nucl Med; 2022 Oct; 63(10):1531-1536. PubMed ID: 36008118
[TBL] [Abstract][Full Text] [Related]
19. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
20. Exploratory analysis of 64 CuCl 2 PET-CT imaging in carcinoma prostate and its comparison with 68 Ga-PSMA-11 and 18 F-FDG PET-CT.
Nazar AK; Kalshetty A; Chakravarty R; Chakraborty S; Basu S
Nucl Med Commun; 2023 Oct; 44(10):910-923. PubMed ID: 37578310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
